IL33 and myeloid sarcoma: From the investigated cytokine panel, we found that the IL-12, IL-15, IL-21, IL-23, and IL-33 levels were much lower in the IA-treated plasma of patients with MS, but only the decreases in the IL-12 and IL-15 levels were statistically significant.